Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRRT with 177Lu-DOTATATE in Children With Refractory or Recurrent Neuroblastoma
NCT03966651Phase 1Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium Lu 177 dotatate in neuroblastoma, sponsored by Institut Claudius Regaud. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started Apr 2023; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT03966651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03966651.